Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 10/20 | 0.58 |
| ▸ | ELOC | Q15369 | 3/20 | 0.58 |
| ▸ | ELOB | Q15370 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | AADAT | Q8N5Z0 | 5/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25769085 | 0.87 | VHL (0.76) | VHLELOCELOB | |
| SCHEMBL21697292 | 0.87 | VHL (0.76) | VHLELOCELOB | |
| SCHEMBL21696696 | 0.87 | VHL (0.54) | VHLELOCELOBCYP3A4CYP2C9 | |
| SCHEMBL15111656 | 0.86 | VHL (0.78) | VHLELOCELOB | |
| SCHEMBL21696541 | 0.86 | VHL (0.57) | VHLELOCELOBCYP3A4CYP2C9 | |
| SCHEMBL21697218 | 0.86 | VHL (0.56) | VHLELOCELOBCYP3A4CYP2C9 | |
| SCHEMBL21696667 | 0.85 | PKM (0.58) | VHLELOCELOBCYP3A4CYP2C9 | |
| SCHEMBL16277209 | 0.85 | VHL (0.57) | VHLELOCELOBCYP3A4CYP2C9 | |
| SCHEMBL16277211 | 0.85 | VHL (0.57) | VHLELOCELOBCYP3A4CYP2C9 | |
| SCHEMBL21696687 | 0.84 | VHL (0.59) | VHLELOCELOBCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127359-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | UNIV YALE (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127359-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | VHL 2/4885ELOC 211/4885ELOB 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.